(Q33347046)

26 July 2017

0 references

ZD0473 treatment in lung cancer: an overview of the clinical trial results (English)

1 reference

26 July 2017

1 reference

4

Mauer A

1 reference

26 July 2017

Treat J

1

1 reference

26 July 2017

Schiller J

2

1 reference

26 July 2017

Quoix E

3

1 reference

26 July 2017

Edelman M

5

1 reference

26 July 2017

Modiano M

6

1 reference

26 July 2017

Bonomi P

7

1 reference

26 July 2017

Ramlau R

8

1 reference

26 July 2017

Lemarie E

9

1 reference

26 July 2017

language of work or name

1 reference

1 December 2002

1 reference

European Journal of Cancer

26 July 2017

1 reference

26 July 2017

38 Suppl 8

1 reference

26 July 2017

S13-8

1 reference

Management of patients with advanced non-small-cell lung cancer

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

Clinical perspectives on platinum resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

A randomized trial fo three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2980016-8

7 January 2021

10.1016/S0959-8049(02)80016-8

Identifiers

DOI

1 reference

release_6pnznikpfjhcfbjcr5rofdf234

26 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6pnznikpfjhcfbjcr5rofdf234

24 November 2022

mapped directly with Wikidata item

1 reference